JNJ-63709178

JNJ-63709178, a bispecific antibody that targets CD3 and CD123, was created under a collaboration between Genmab and Janssen using Genmab's DuoBody technology. JNJ-63709178 is being investigated in a Phase I clinical study to treat relapsed or refractory acute myeloid leukemia.

Back to top

Acute myeloid leukemia (AML) begins in the bone marrow and often moves quickly into the blood. It may then spread to other parts of the body including the lymph nodes, liver, spleen and central nervous system1.  The average age of AML patients is 67, with the disease uncommon in people under 452. According to the American Cancer Society, there will be 19,950 new cases of AML in the United States in 20162.


1 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/overviewguide/leukemia-aml-overview-what-is-aml
2 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-key-statistics


Back to top